CSL Limited (ASX: CSL) is slowly expanding its Research & Development (R&D) capabilities and pipeline to deliver a highly distinguished product portfolio mix and focusing on a broader range of patients’ unmet needs.
- The company is building its leadership in plasma therapies by identifying emerging new medicines;
- To support this approach, CSL has forged targeted innovation partnerships near its R&D locations;
- CSL also released details on progress for a novel treatment of asthma, which has advanced to Phase 1 trials.
At AEST 01:20PM, the stock was trading at $276.100 per share, down by 0.648% from its previous close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.